PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21282435-0	2011	Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.	Darunavir	84-93	Pr55(Gag)	Human immunodeficiency virus 1	25-28	
18765410-0	2008	Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.	Darunavir	40-49	Pr55(Gag)	Human immunodeficiency virus 1	10-13	
18765410-1	2008	OBJECTIVES: To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations.	Darunavir	120-129	Pr55(Gag)	Human immunodeficiency virus 1	62-65	
18765410-6	2008	The I437T/V mutation in gag and the L76V mutation in the protease were associated with a lower risk of selecting darunavir resistance mutations.	Darunavir	113-122	Pr55(Gag)	Human immunodeficiency virus 1	24-27	
18765410-7	2008	CONCLUSIONS: In these PI-treated patients experiencing treatment failure of a darunavir-containing regimen, we showed that mutations in the gag region NC-p1/TFP-p6/p6pol may influence the selection of darunavir resistance mutations; in particular, the I437T/V gag mutation that confers resistance to PIs reduces the selection of such mutations.	Darunavir	78-87	Pr55(Gag)	Human immunodeficiency virus 1	140-143	
18765410-7	2008	CONCLUSIONS: In these PI-treated patients experiencing treatment failure of a darunavir-containing regimen, we showed that mutations in the gag region NC-p1/TFP-p6/p6pol may influence the selection of darunavir resistance mutations; in particular, the I437T/V gag mutation that confers resistance to PIs reduces the selection of such mutations.	Darunavir	78-87	Pr55(Gag)	Human immunodeficiency virus 1	260-263	
18765410-7	2008	CONCLUSIONS: In these PI-treated patients experiencing treatment failure of a darunavir-containing regimen, we showed that mutations in the gag region NC-p1/TFP-p6/p6pol may influence the selection of darunavir resistance mutations; in particular, the I437T/V gag mutation that confers resistance to PIs reduces the selection of such mutations.	Darunavir	201-210	Pr55(Gag)	Human immunodeficiency virus 1	140-143	
18765410-7	2008	CONCLUSIONS: In these PI-treated patients experiencing treatment failure of a darunavir-containing regimen, we showed that mutations in the gag region NC-p1/TFP-p6/p6pol may influence the selection of darunavir resistance mutations; in particular, the I437T/V gag mutation that confers resistance to PIs reduces the selection of such mutations.	Darunavir	201-210	Pr55(Gag)	Human immunodeficiency virus 1	260-263	
18765410-8	2008	Virus with L76V in protease or I437T/V in gag may be already resistant to darunavir and, therefore, no additional resistance mutations need to be selected.	Darunavir	74-83	Pr55(Gag)	Human immunodeficiency virus 1	42-45	
32556165-0	2020	HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.	Darunavir	51-60	Pr55(Gag)	Human immunodeficiency virus 1	6-9	
32556165-11	2020	Low susceptibility to darunavir was dependent on the Gag sequence context.	Darunavir	22-31	Pr55(Gag)	Human immunodeficiency virus 1	53-56	
32556165-13	2020	CONCLUSIONS: Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness.	Darunavir	38-47	Pr55(Gag)	Human immunodeficiency virus 1	13-16	
30573649-8	2019	However, in the presence of the related Gag, L38 N L showed reduced susceptibility to darunavir while remaining susceptible to LPV and ATV.	Darunavir	86-95	Pr55(Gag)	Human immunodeficiency virus 1	40-43	
30573649-10	2019	The reduced susceptibility to darunavir and decrease in RC may be due to PTAPP duplication in the related Gag.	Darunavir	30-39	Pr55(Gag)	Human immunodeficiency virus 1	106-109